Sutter Santa Rosa Regional Hospital
- Type
- Teaching hospital
- Where
- SANTA ROSA, CA
- Medicare CCN
- 050291
- Received
- $194,949 in 17 records, 2024 ($10,925 general, $184,024 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 7 | $10,925 |
| 2024 | Research payment | 10 | $184,024 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| AstraZeneca UK Limited | 1 | $59,447 | 2024 |
| AstraZeneca Pharmaceuticals LP | 3 | $49,328 | 2024 |
| Hoffmann-La Roche Limited | 3 | $30,202 | 2024 |
| Alexion Pharmaceuticals, Inc. | 1 | $20,900 | 2024 |
| ABBVIE INC. | 2 | $19,039 | 2024 |
| Biosense Webster, Inc. | 1 | $7,607 | 2024 |
| Pacira Pharmaceuticals Incorporated | 2 | $5,174 | 2024 |
| Linvatec Corporation | 1 | $2,893 | 2024 |
| Masimo Corporation | 1 | $171 | 2024 |
| Medline Industries LP | 1 | $149 | 2024 |
| Zimmer Biomet Holdings, Inc. | 1 | $36 | 2024 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 10 | $184,024 |
| Long term medical supply or device loan | 4 | $8,239 |
| Space rental or facility fees (teaching hospital only) | 1 | $2,500 |
| Debt forgiveness | 2 | $186 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | ABBVIE INC. | $1,772 | Research payment | In-kind items and services | M21-341 ATH Ph 2b Armour Thyroid vs Synthetic T4 (ATH-MD-01) (3014-301-002) | 2024 | |
| 2024-12-31 | Masimo Corporation | $171 | Long term medical supply or device loan | Cash or cash equivalent | EMMA and ISA Device, Devices | 2024 | |
| 2024-12-31 | Medline Industries LP | $149 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Zimmer Biomet Holdings, Inc. | $36 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-10-01 | Linvatec Corporation | $2,893 | Long term medical supply or device loan | In-kind items and services | AIRSEAL Device, GENERAL SURGERY | 2024 | |
| 2024-09-17 | Alexion Pharmaceuticals, Inc. | $20,900 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN205 | 2024 | |
| 2024-08-23 | AstraZeneca Pharmaceuticals LP | $42,868 | Research payment | Cash or cash equivalent | A Two Part Phase IIa b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-ranging Study to A | 2024 | |
| 2024-08-07 | AstraZeneca UK Limited | $59,447 | Research payment | Cash or cash equivalent | Truqap Drug, Oncology | A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetax | 2024 |
| 2024-06-25 | Pacira Pharmaceuticals Incorporated | $2,587 | Long term medical supply or device loan | In-kind items and services | Iovera Device, Pain Management | 2024 | |
| 2024-06-25 | Pacira Pharmaceuticals Incorporated | $2,587 | Long term medical supply or device loan | In-kind items and services | Iovera Device, Pain Management | 2024 | |
| 2024-06-06 | ABBVIE INC. | $17,267 | Research payment | Cash or cash equivalent | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse | 2024 | |
| 2024-05-29 | AstraZeneca Pharmaceuticals LP | $3,960 | Research payment | Cash or cash equivalent | FARXIGA Drug, Cardiovascular and Metabolism | Dapagliflozin in Acute Decompensated Heart Failure | 2024 |
| 2024-05-03 | AstraZeneca Pharmaceuticals LP | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2024 | |
| 2024-01-26 | Biosense Webster, Inc. | $7,607 | Research payment | Cash or cash equivalent | Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation with the BWI IRE Ablation System | 2024 | |
| 2024-01-16 | Hoffmann-La Roche Limited | $26,670 | Research payment | Cash or cash equivalent | A Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy | 2024 | |
| 2024-01-16 | Hoffmann-La Roche Limited | $2,781 | Research payment | Cash or cash equivalent | A Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy | 2024 | |
| 2024-01-16 | Hoffmann-La Roche Limited | $750 | Research payment | Cash or cash equivalent | A Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Santa Rosa, CA, county Sonoma County, CA, state California; placed by its city name.
| Measure | Place (city or town) Santa Rosa, CA | County Sonoma County, CA | State California |
|---|---|---|---|
| Population B01003 | 177,090 | 485,040 | 39,287,377 |
| Population, 2020 census P1 | 178,127 | 488,863 | 39,538,223 |
| Median age B01002 | 41.2 | 42.9 | 37.9 |
| Under 18 B01001 | 20.1% | 19.0% | 22.0% |
| 65 and over B01001 | 19.0% | 21.5% | 15.7% |
| Households B11001 | 68,321 | 190,998 | 13,548,091 |
| Foreign born B05002 | 21.2% | 16.8% | 27.0% |
| Median household income B19013 | $99,060 | $104,674 | $99,122 |
| Median family income B19113 | $120,944 | $126,900 | $113,346 |
| Per capita income B19301 | $52,066 | $56,640 | $49,513 |
| Poverty rate B17001 | 9.7% | 8.9% | 12.0% |
| Unemployment rate B23025 | 6.3% | 5.7% | 6.6% |
| Civilian labor force B23025 | 96,710 | 258,155 | 20,068,466 |
| Mean commute (minutes) B08013 | 22.9 | 25.1 | 28.7 |
| Bachelor's degree or higher B15003 | 35.1% | 38.5% | 37.1% |
| Housing units B25001 | 71,382 | 207,699 | 14,644,735 |
| Owner-occupied B25003 | 56.7% | 62.6% | 55.9% |
| Renters B25003 | 43.3% | 37.4% | 44.1% |
| Median home value B25077 | $713,900 | $815,500 | $734,700 |
| Median gross rent B25064 | $2,152 | $2,158 | $2,036 |
| White, not Hispanic B03002 | 48.7% | 57.9% | 33.8% |
| Black B03002 | 1.9% | 1.5% | 5.2% |
| Hispanic or Latino B03002 | 37.4% | 30.0% | 40.2% |
| Asian B03002 | 6.3% | 4.3% | 15.3% |
| American Indian and Alaska Native B03002 | 0.3% | 0.3% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Santa Rosa, CA.
Comments